Algernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT...

Red Light Holland Appoints New Chief Financial Officer

Psychedelic Bulletin: MindMed Announces R(-)-MDMA Program; Psilocybin for Anxiety Study Secures...

PTSF83 – Abuse in Psychedelics: Complicity and Groupthink

Addressing Abuse in Psychedelic Spaces

MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol...

Awakn Life Sciences Identifies New Chemical Series via Its Drug Discovery...

Cybin Announces Launch of EMBARK Psychedelic Facilitator Training Program

MYND Life Sciences Signs Agreement to Acquire Rights for the Use...

Entheon Biomedical Provides Corporate Update on Studies and Clinical Trials

Load more